BioDelivery Sciences to Report First Quarter 2019 Financial Results
25 avr. 2019 16h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock
10 avr. 2019 16h07 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 10, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced that it is commencing an underwritten public...
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
10 avr. 2019 16h06 HE
|
BioDelivery Sciences International, Inc.
Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel treatment option for OIC ...
Study of SPR Therapeutics’ Peripheral Nerve Stimulation System Demonstrates Significant and Sustained Relief of Post-Amputation Pain
08 avr. 2019 13h39 HE
|
SPR Therapeutics, Inc.
CLEVELAND, April 08, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today announced the results of a study of its SPRINT® Peripheral...
Wearable Healthcare/Medical Devices Market To Reach USD 27.49 Billion By 2026 | CAGR: 18.5% | Reports And Data
27 févr. 2019 10h30 HE
|
Reports And Data
Growing shift of healthcare providers towards wireless connectivity coupled with increasing incidence of diseases including obesity and diabetes is expected to stimulate market growth. Market Size...
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
21 févr. 2019 07h45 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
04 févr. 2019 08h03 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
15 janv. 2019 07h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Jan. 15, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
SPR Therapeutics Announces First Use of SPRINT endura Peripheral Nerve Stimulation System to treat Complex Regional Pain Syndrome
15 nov. 2018 08h00 HE
|
SPR Therapeutics, Inc.
SPRINT System is the least invasive PNS device for CRPS CLEVELAND, Nov. 15, 2018 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, today...
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
08 nov. 2018 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...